Daiwa initiates Vertex Pharmaceuticals Incorporated [VRTX] at Outperform and sets price target at $250
Daiwa launched its Vertex Pharmaceuticals Incorporated [NASDAQ:VRTX] rating to the equivalent of Outperform and assigned the price target of $250, in a research note dated December 30, 2020. That figure represents around a 7.07% premium from where the company’s shares closed on Tuesday. Other analysts also revised their coverage, with RBC Capital Mkts’s analysts upgrading […]